Aclaris Therapeutics, Inc.ACRSEarnings & Financial Report
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for immunological, inflammatory, and dermatological diseases. Its pipeline includes candidates for unmet needs like alopecia areata and vitiligo, serving global patient groups.
ACRS Q4 FY2025 Key Financial Metrics
Revenue
$1.3M
Gross Profit
$763.0K
Operating Profit
N/A
Net Profit
N/A
Gross Margin
58.9%
Operating Margin
N/A
Net Margin
N/A
YoY Growth
-85.9%
Aclaris Therapeutics, Inc. Q4 FY2025 Financial Summary
Aclaris Therapeutics, Inc. reported revenue of $1.3M (down 85.9% YoY) for Q4 FY2025, with a net profit of N/A (up 79.5% YoY) (N/A margin). Cost of goods sold was $532.0K.
Key Financial Metrics
| Total Revenue | $1.3M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 58.9% |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Aclaris Therapeutics, Inc. Annual Revenue by Year
Aclaris Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $7.8M).
Aclaris Therapeutics, Inc. Quarterly Revenue & Net Profit History
Aclaris Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.3M | -85.9% | N/A | N/A |
| Q3 FY2025 | $3.3M | -24.1% | $-14.6M | -443.0% |
| Q2 FY2025 | $1.8M | -35.8% | $-15.4M | -868.3% |
| Q1 FY2025 | $1.5M | -39.3% | $-15.1M | -1036.8% |
| Q4 FY2024 | $9.2M | -47.6% | $-96.6M | -1048.3% |
| Q3 FY2024 | $4.3M | -53.2% | $-7.6M | -174.6% |
| Q2 FY2024 | $2.8M | +48.0% | $-11.0M | -397.2% |
| Q1 FY2024 | $2.4M | -5.1% | $-16.9M | -706.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $2.8M | $4.3M | $9.2M | $1.5M | $1.8M | $3.3M | $1.3M |
| YoY Growth | -5.1% | 48.0% | -53.2% | -47.6% | -39.3% | -35.8% | -24.1% | -85.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $174.1M | $161.1M | $182.4M | $220.3M | $198.1M | $189.1M | $175.5M | $160.5M |
| Liabilities | $32.1M | $27.2M | $52.2M | $64.8M | $54.0M | $57.4M | $55.4M | $57.4M |
| Equity | $142.0M | $133.8M | $130.2M | $155.6M | $144.1M | $131.7M | $120.1M | $103.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-20.8M | $-12.3M | $22.0M | $-8.9M | $-13.1M | $-10.0M | $-10.9M | $-47.1M |